Latest Tax Incentives News

Skin Elements Limited reported a 13% revenue increase and a 20% reduction in net loss for FY2025, as it progresses commercial roll-out of its natural biotech products including ECO-Nurture and SuprCuvr.

Radiopharm Theranostics reported a dramatic revenue surge to $3.63 million alongside a 20% reduction in net loss for FY2025, while increasing its stake in Radiopharm Ventures to 75%.

Constellation Technologies Limited has reported a 34% revenue increase and a return to profitability in FY25, driven by strong adoption of its IoT-based food safety solutions across multiple sectors. The company is scaling its innovative Callisto platform and hardware offerings to capture broader market opportunities.

Careteq Limited has returned to profitability in FY25, reporting a 5.4% revenue increase and a 171% jump in underlying EBITDA, driven by strategic divestments and acquisitions.

Careteq Limited reported a dramatic reduction in its FY25 loss to just $72,204, down from $2.67 million the prior year, while facing a significant $3.6 million dispute with the Australian Taxation Office over R&D tax claims.

Acrux Ltd reported a 44% revenue decline and a modest increase in net loss for FY25, while expanding its US topical generics portfolio and entering the Saudi Arabian market. The company signals a strategic pivot amid intensifying competition and lower returns.

Orbital Corporation Limited posted a $4.3 million net loss for FY25, reflecting a revenue decline amid production transitions. The company secured a $3 million capital raise to support new UAV engine development and expand its global footprint.

LTR Pharma’s FY25 results reveal a transformative year highlighted by SPONTAN’s rapid absorption and strategic partnerships that pave the way for US market entry.

Gumtree Australia Markets Limited reports a transformational FY25 marked by a $6.8 million Capital Markets division sale, a near doubling of EBITDA, and promising expansions in transactional services and partnerships.

NeuroScientific Biopharmaceuticals reported a $1.85 million loss for FY25, driven by reduced R&D incentives and increased development costs following its acquisition of StemSmart™ technology. The company is advancing clinical programs, including a Special Access Scheme for Crohn’s disease.

Argenica Therapeutics reported a 34% revenue increase driven by R&D incentives but saw losses widen by 31% due to intensified clinical trial activity. The company is progressing its ARG-007 Phase 2 stroke trial and engaging with the FDA to lift a clinical hold.

Syntara Limited reported a significantly reduced loss for FY2025, driven by clinical progress and capital raises, while advancing its lead drug amsulostat with FDA Fast Track designation. The company also navigates ongoing payment disputes following the sale of its mannitol respiratory business.